Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS news (Ticker: ARTV), a resource for investors and traders seeking the latest updates and insights on ARTIVA BIOTHERAPEUTICS stock.
About Artiva Biotherapeutics Inc
Artiva Biotherapeutics Inc (Nasdaq: ARTV) is a clinical-stage biotechnology company dedicated to transforming the landscape of cell therapies for autoimmune diseases and cancers. Headquartered in San Diego, California, Artiva specializes in the development of off-the-shelf, allogeneic natural killer (NK) cell therapies, designed to be effective, safe, and accessible to patients worldwide. By leveraging advanced NK cell manufacturing technology, Artiva is addressing critical challenges in scalability and accessibility that have traditionally hindered the adoption of cell therapies.
Core Business and Innovative Therapies
At the heart of Artiva’s innovation is its flagship program, AlloNK®, an allogeneic, cryopreserved NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity (ADCC). This mechanism improves the depletion of B-cells, offering a promising therapeutic approach for autoimmune diseases such as systemic lupus erythematosus, including lupus nephritis. AlloNK® is currently undergoing clinical trials to evaluate its efficacy and safety across multiple autoimmune indications.
In addition to AlloNK®, Artiva’s pipeline includes CAR-NK (chimeric antigen receptor NK) candidates targeting both hematologic malignancies and solid tumors. These therapies aim to harness the innate tumor-killing capabilities of NK cells while incorporating innovative engineering to enhance specificity and potency against cancer cells. By focusing on non-genetically modified NK cells, Artiva differentiates itself from other cell therapy companies that rely on complex genetic modifications, potentially reducing manufacturing costs and regulatory barriers.
Strategic Partnerships and Market Position
Artiva was founded in 2019 as a spinout of GC Cell, a leading healthcare company based in South Korea. Through a strategic partnership, Artiva has exclusive worldwide rights (excluding Asia, Australia, and New Zealand) to GC Cell’s NK cell manufacturing technology and programs. This collaboration provides Artiva with a robust technological foundation and access to cutting-edge manufacturing capabilities, enabling the scalable production of its therapies.
Operating within the rapidly evolving biopharmaceutical landscape, Artiva faces competition from companies developing NK cell therapies, CAR-T therapies, and other immuno-oncology solutions. However, its focus on off-the-shelf, cryopreserved cell therapies and its emphasis on accessibility and safety position it uniquely in the market.
Market Potential and Challenges
The global market for cell therapies is expanding rapidly, driven by advancements in immunotherapy and increasing demand for effective treatments for autoimmune diseases and cancers. Artiva’s approach to developing scalable, off-the-shelf therapies addresses critical gaps in the market, particularly the need for cost-effective and readily available solutions. However, the company must navigate significant challenges, including regulatory approvals, clinical trial success, and competitive pressures from other biotechnology firms.
Commitment to Patients and Innovation
Artiva’s mission is rooted in a commitment to improving patient outcomes through innovative cell therapies. By focusing on the development of accessible and effective treatments, the company aims to make a meaningful impact on the lives of patients with devastating autoimmune diseases and cancers. Its robust pipeline, strategic partnerships, and focus on non-genetically modified NK cells underscore its dedication to advancing the field of immunotherapy.
As a pioneering force in the biopharmaceutical industry, Artiva Biotherapeutics Inc is poised to play a significant role in shaping the future of cell therapies, offering hope to patients and addressing critical unmet medical needs.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 5, 2025, at 2:30 p.m. EST in Boston, MA.
The management team will be available for in-person meetings with registered conference attendees. A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section on Artivabio.com, with the replay remaining available for 90 days after the event.
Artiva Biotherapeutics (ARTV) has appointed Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker, currently interim Chief Development Officer at Cue Biopharma, brings over 20 years of pharmaceutical industry experience, including a 19-year tenure at Johnson & Johnson where he led the development of major immunology drugs like Remicade, Simponi, and Stelara, which achieved over $20 billion in peak sales.
Previously, Dr. Baker served as CEO and Founder of Kira Biotech and Executive Director on Galapagos Therapeutics' board. He holds a B.A. in Biology from Gettysburg College and an M.D. from the University of Pennsylvania, with extensive medical training and academic experience in Rheumatology.
Artiva Biotherapeutics (ARTV) reported Q3 2024 financial results, highlighting a strong cash position of $199.6 million as of September 30, 2024, expected to fund operations through 2026. The company completed an upsized $179.0 million IPO in July 2024. Q3 showed a net loss of $17.5 million compared to net income of $11.3 million in Q3 2023. R&D expenses were $13.5 million, while G&A expenses increased to $4.8 million. The company expanded its Board with Dr. Alison Moore and expects initial data for AlloNK® in autoimmune indications in H1 2025.
Artiva Biotherapeutics (Nasdaq: ARTV) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 20, 2024, at 3:30 p.m. GMT in London. The clinical-stage biotechnology company, focused on developing cell therapies for autoimmune diseases and cancers, will make the session available via live webcast through their website's Investor section. Management team members will also conduct in-person meetings with registered conference attendees. A replay of the webcast will remain accessible for 90 days post-event.
Artiva Biotherapeutics (Nasdaq: ARTV) has appointed Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, with expertise in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. and was formerly CTO of Allogene Therapeutics.
Fred Aslan, M.D., CEO of Artiva, highlighted Dr. Moore's extensive experience in manufacturing and technical operations, particularly in allogeneic cell therapies. The company believes its manufacturing process for AlloNK® sets it apart from peers, potentially accelerating the path to bring this experimental therapy to patients with autoimmune diseases and cancers.
Dr. Moore expressed enthusiasm for AlloNK®'s scalable and robust manufacturing process, noting its simplified approach due to the lack of genetic engineering. She aims to help realize the full potential of AlloNK® in treating autoimmune diseases and cancer.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. The company's management will engage in a fireside chat on September 18, 2024, at 8:00 a.m. ET in New York City.
Investors and the public can access a live webcast of the chat through the 'Investors' section on Artivabio.com. A replay will be available for 90 days after the event. Additionally, Artiva's management team will be available for in-person investor meetings during the conference.
Artiva Biotherapeutics (Nasdaq: ARTV) reported Q2 2024 financial results and recent business highlights. Key points include:
- Successful completion of a $179.0 million upsized IPO, extending cash runway through 2026
- Initiation of an investigator-initiated basket trial exploring AlloNK® in multiple autoimmune indications
- Treatment of the first patient in a Phase 1/1b trial for lupus nephritis (LN) and systemic lupus erythematosus (SLE)
- Q2 2024 financial results: $46.6 million in cash and investments (pre-IPO), $12.3 million in R&D expenses, and a net loss of $17.8 million
Artiva aims to report initial data on autoimmune indications from ongoing trials in the first half of 2025.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotechnology company, announced the pricing of its upsized initial public offering (IPO) of 13,920,000 shares of common stock at $12.00 per share. This offering is expected to yield gross proceeds of approximately $167.0 million, before underwriting discounts and offering expenses. Additionally, underwriters have a 30-day option to purchase up to 2,088,000 additional shares at the IPO price. Shares will begin trading on Nasdaq under “ARTV” on July 19, 2024, with the offering closing on July 22, 2024, pending customary conditions. Jefferies, TD Cowen, and Cantor are joint book-running managers, with Wedbush PacGrow and Needham & Company as co-lead managers.
FAQ
What is the current stock price of ARTIVA BIOTHERAPEUTICS (ARTV)?
What is the market cap of ARTIVA BIOTHERAPEUTICS (ARTV)?
What does Artiva Biotherapeutics Inc specialize in?
What is AlloNK®?
How does Artiva differentiate itself from competitors?
What are CAR-NK therapies in Artiva’s pipeline?
What is the significance of Artiva’s partnership with GC Cell?
What challenges does Artiva face in its market?
What is the market potential for Artiva’s therapies?
Where is Artiva Biotherapeutics headquartered?
What is Artiva’s mission?
